Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now
Oliver Sartor MD
Oliver Sartor MD Advisory Board
Benjamin Anderson MD, FACS
Benjamin O. Anderson MD, FACS Advisory Board
Eric Jonasch MD
Eric Jonasch MD Advisory Board
See All Experts
featured
Published in Oncology and
1 other channel

Expert Opinion / Conference Coverage · June 17, 2015

ASCO 2015 Recap: Renal Cell Carcinoma

Tony Nimeh MD
Interview by
Tony Nimeh MD
Eric Jonasch MD
Interview with
Eric Jonasch MD

 

 Save  Recommend
 Share

Additional Info

  1. Motzer R, Hutson T, Glen H, et al Randomized phase II, three-arm trial of lenvatinib [LEN], everolimus [EVE], and LEN+EVE in patients with metastatic renal cell carcinoma. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2015; Chicago, IL. Abstract 4506.
  2. Bjarnason GA, Knox JJ, Kollmannsberger CK, et al. Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2015; Chicago, IL. Abstract 4555.
  3. Armstrong AJ, Broderick S, Eisen T, et al. Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma [ASPEN]. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2015; Chicago, IL. Abstract 4507.
  4. Hammers HJ, Plimack ER, Infante JR, et al. Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2015; Chicago, IL. Abstract 4516.
  5. Plimack ER, Hammers HJ, Rini BI, et al. Updated survival results from a randomized, dose-ranging phase II study of nivolumab in metastatic renal cell carcinoma. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2015; Chicago, IL. Abstract 4553.
  6. Liu X, Hoang A, Zhou L, et al. Resistance to anti-angiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma [published online May 26, 2015]. Cancer Immunol Res. doi: 10.1158/2326-6066.CIR-14-0244.

Disclosure statements are available on the authors' profiles:

Eric Jonasch MD

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading

Most Read This Week

Recently Updated